Keywords
Quercetin
Type 2 Diabetes Mellitus
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To simulate pharmacokinetic and pharmacodynamic analyzes of quercetin, using in silico methods and report its effect in combating hyperglycemia, through a literature review. Methods: This is a mixed study, descriptive-exploratory and cross-sectional in nature. The data was collected on the Swiss ADME and Swiss Target Prediction platforms, both available online and free of charge. Pharmacokinetic analyzes were carried out in them, including interaction with cytochrome P450 enzymes and pharmacodynamic properties were evaluated, with the prediction of biological targets, respectively. The Pubmed and Google Scholar databases were used to carry out an analytical bibliographic research on the therapeutic potential of quercetin in type 2 Diabetes Mellitus (DM2). Results: Good oral bioavailability was demonstrated, complying with the parameters of the Lapinsk Rule. Demonstrated promising results regarding pharmacokinetic parameters, however it presented an inhibitory effect on CYP1A2, CYPD6 and CYP3A4 proteins. Interacted with around 100 biological targets, 33.3% of which were kinase, 6.7% lyase, 6.7% protease, 6.7% cytochrome P450, 13.3% G protein-coupled receptor, 13.3% enzyme and 20% oxidoreductase. Conclusion: The potential of quercetin for the development of new hypoglycemic drugs was concluded. However, there is a greater need for studies to evaluate its therapy and the safety of its use.
References
ALKHALIDY H, et al. Kaempferola meliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obesity mice. J Nutr Biochem, 2018; 90-101.
ANKER JVD, et al. Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol, 2018; S10-S25.
BHATTACHARYA S, et al. Caffeic acid, naringenin and quercetinenhance glucose-stimulated insulin secretion and glucose sensitivity in INS-1E cells. Diabetes Obes Metab, 2003; 602-612.
CAIA NARRA e DE FREITAS JCR. Avaliação das propriedades farmacocinéticas de um candidato a fármaco derivado da d-glicose. CONIMAS, 2019.
CHEN S, et al. Therapeutic Effects of Quercetin on Inflammation, Obesity, and Type 2 Diabetes. Inflammatory mediators, 2016; 1-5.
DARENSKAYA MA, et al. Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bulletin of experimental biology and medicine, 2021; 171(2): 179-189.
EID HM e HADDAD PS. The Antidiabetic Potential of Quercetin: Underlying Mechanisms. Current medicinal chemistry, 2017; 24(4): 355-364.
EL KHOURY G, et al. Prevalence, Correlates and Management of Hyperglycemia in Diabetic Non-critically Ill Patients at a Tertiary Care Center in Lebanon. Current diabetes reviews, 2019; 15(2): 133-140.
GRAF AB, et al. Rat Gastrointestinal Tissues Metabolize Quercetin. The Journal of Nutrition, 2006; 39-44.
GUPTA P, et al. Emerging role of protein kinases in diabetes mellitus: From mechanism to therapy. Advances in protein chemistry and structural biology, 2021; 124: 47-85.
GUYOMARD V, MYINT PK. Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke. Current treatment options in cardiovascular medicine, 2009; 11(3): 201-11.
HAWKINS BT e DAVIS TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacological reviews, 2005; 173-185.
LI Y, et al. Quercetin, Inflammation and Immunity. Nutrients, 2016; 8(3): 167.
LIN K, et al. An Interpretable Double-Scale Attention Model for Enzyme Protein Class Prediction Based on Transformer Encoders and Multi-Scale Convolutions. Frontiers in genetics, 2022; 1-20.
LUCAS V, et al. Bioactivity of dietary polyphenols: The role of metabolites. Critical Reviews in Food Science and Nutrition, 2019; 1-35.
MIRZAEI M. Ciência e engenharia in silico. Adv J Sci Eng, 2020; 1(1): 1-2.
MOHO SV, et al. Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome P450 enzymes, and on OATP, BCRP and MRP2 transporters. Nutrients, 2020; 12(8): 2306.
OHDY e OLEFSKY JM. G protein-coupled receptors as targets for antidiabetic therapeutics. Nature reviews Drug discovery, 2016; 15(3): 161-172.
OLTHOF MR, et al. Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans. Human Nutrition and Metabolism—Research Communication, 2000; 1200-1203.
OTEIZA PI, et al. Flavonoids and the gastrointestinal tract: Local and systemic effects. Molecular Aspects of Medicine, 2018; 41-49.
PAN D, et al. The role of protein kinase C in diabetic microvascular complications. Frontiers in Endocrinology, 2022; 13: 973058.
PARDO MR, et al. Bioavailability of magnesium food supplements: A systematic review. Nutrition, 2021; 111294.
PATEL RV, et al. Therapeutic potential of quercetin as a cardiovascular agent. European Journal of Medicinal Chemistry, 2018; 889-904.
PATEL R, et al. Pharmaceutical Excipients and Drug Metabolism: A Mini-Review. Int J Mol Sci, 2020; 1-21.
POET TS e MCDOUGAL JN. Skin absorption and human risk assessment. Chem Biol Interact, 2002; 19–34.
RODRIGUES GS, et al. Uso de softwares livres em aula prática sobre filtros moleculares de biodisponibilidade oral de fármacos. Química Nova, 2021; 44: 1036-1044.
SERRA CA, et al. Quercetin prevents insulin dysfunction in hypertensive animals. J Diabetes Metab Disord., 2022, 408-417.
SIDHU JS, et al. Trends in small organic fluorescent scaffolds for detection of oxidoreductase. Biosens Bioelectron, 2021; 113441.
TSAO JP, et al. Short-Term Oral Quercetin Supplementation Improves Post-exercise Insulin Sensitivity, Antioxidant Capacity and Enhances Subsequent Cycling Time to Exhaustion in Healthy Adults: A Pilot Study. Front Nutr, 2022; 9: 1-5.
VAN DE WATERBEEMDH e GIFFORDE. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov., 2003; 2(3): 192-204.
WANG Y e MA H. Protein kinase profiling assays: a technology review. Drug Discov Today Technol, 2015; 1-8.
WEIS WI e KOBILKA BK. The Molecular Basis of G Protein–Coupled Receptor Activation. Annu Rev Biochem, 2018; 897-919.
XIE J, et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials, 2019; 1-20.